← back to search

Xiangshun Kong

Hebei Medical University · CN
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, and Breast Cancer Treatment Studies.
h-index
5
citations
117
works
16
NIH funding
primary concept
email

Recent publications

Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study
Breast Cancer Research 2025cited by 3position: middledoi
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor–Positive and <i>ERBB2</i>-Negative Advanced Breast Cancer After Endocrine Therapy
JAMA Oncology 2025cited by 2position: middledoi
Abstract PO2-02-05: CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor-positive, HER2-negative stage II-III breast cancer: a single-arm exploratory trial
Cancer Research 2024cited by 1position: middledoi
Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
Frontiers in Oncology 2022cited by 13position: middledoi
miR‑217‑5p suppresses epithelial‑mesenchymal transition and the NF‑κB signaling pathway in breast cancer via targeting of metadherin
Oncology Letters 2022cited by 10position: middledoi
A randomized trial of pegylated recombinant human granulocyte-colony stimulating factor to prevent febrile neutropenia in breast cancer after chemotherapy.
Journal of Clinical Oncology 2022cited by 1position: middledoi
Grape Seed Procyanidins Inhibit the Growth of Breast Cancer MCF-7 Cells by Down-Regulating the EGFR/VEGF/MMP9 Pathway
Natural Product Communications 2021cited by 12position: middledoi
Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
Medicine 2021cited by 3position: middledoi
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020
EClinicalMedicine 2020cited by 51position: middledoi
Expression of Rab5a correlates with tumor progression in pancreatic carcinoma
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2017cited by 17position: middledoi
Immunotherapeutic effects of 1-methyltroptophan combined with dendritic cells vaccine in mice with pancreatic carcinoma
Zhonghua shiyan waike zazhi 2013cited by 0position: middledoi
Relationship between serum adiponectin levels and clinicopahtological features of patients with breast cancer
Zhonghua shiyan waike zazhi 2012cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yuntao Li · Universidad del Noreste4 papers (2022–2025)Meiqi Wang · Hebei Medical University4 papers (2022–2025)Lina Zhang · Hebei Medical University3 papers (2022–2025)Cuizhi Geng · Hebei Medical University3 papers (2022–2025) · 3 papers (2021–2025)Yanshou Zhang · Hebei Medical University3 papers (2022–2025)Zhisheng Zhang · Shanghai Medical College of Fudan University2 papers (2024–2025)Yuandong Li · Energy Institute2 papers (2012–2013)Jiaxing Wang · Shenzhen Polytechnic University2 papers (2024–2025)Jiajie Shi · Hebei Medical University2 papers (2024–2025)Jianjun Han · Shandong University2 papers (2021–2024)Chao Yang · First Affiliated Hospital of GuangXi Medical University2 papers (2021–2025) · 2 papers (2024–2025) · 2 papers (2024–2025)Xiaochun Wang · Shanxi Medical University2 papers (2024–2025)Yueping Liu · Hebei Medical University2 papers (2022–2025)Donghui Ji · Hebei Medical University2 papers (2013–2017)Zhenchuan Song · Hebei Medical University2 papers (2022–2022)Fanlei Kong · Qilu Hospital of Shandong University1 papers (2021–2021) · 1 papers (2022–2022)